| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Oregon Health and Science University (OHSU) Cancer Institute [F. C., A. T., A. S., A. H., T. B., M. C. H., C. L. C.], Departments of Pathology [F. C., C. L. C.], and Ophthalmology [D. W.], and Division of Hematology and Oncology [M. C. H.], OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, and Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195 [B. P. R.]
Uveal melanoma (UM) and cutaneous melanoma (CM) differ significantly in their epidemiological, clinical, immunophenotypical, and cytogenetic features, but the molecular basis for these differences has not been delineated. CMs frequently harbor an activating mutation in either NRAS or the RAS-regulated kinase BRAF, suggesting that either of these oncogenes may increase signaling through the mitogen-activated protein (MAP) kinase pathway and promote melanoma development. The aim of this study was to examine BRAF and NRAS gene mutations in UM. Genomic DNA from CM and UM was screened for mutations in BRAF exons 11 and 15 and NRAS exons 1 and 2 using a combination of denaturing high-performance liquid chromatography and direct sequencing. Mutations in BRAF exon 15 were detected in 16 (36.4%) of 44 CMs and 0 (0%) of 62 UMs. The most common mutation in CM was V599E, but a novel point mutation (L596Q) was identified in two cases and an in-frame deletion/insertion (VKSRWK599–604D) was discovered in one case. No BRAF exon 11 mutations were observed among seven CMs and nine UMs that were wild-type for exon 15. Mutation of NRAS exon 2 was rare in CM [1 (3.7%) of 27] and absent in UM [0 (0%) of 47]. No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway.
This article has been cited by other articles:
|
|
 |
|
  G. Lefevre, N. Babchia, A. Calipel, F. Mouriaux, A.-M. Faussat, S. Mrzyk, and F. Mascarelli Activation of the FGF2/FGFR1 Autocrine Loop for Cell Proliferation and Survival in Uveal Melanoma Cells Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1047 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Onken, L. A. Worley, M. D. Long, S. Duan, M. L. Council, A. M. Bowcock, and J. W. Harbour Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5230 - 5234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Beadling, E. Jacobson-Dunlop, F. S. Hodi, C. Le, A. Warrick, J. Patterson, A. Town, A. Harlow, F. Cruz III, S. Azar, et al. KIT Gene Mutations and Copy Number in Melanoma Subtypes Clin. Cancer Res., November 1, 2008; 14(21): 6821 - 6828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, G. Masi, I. M. Boschin, E. Lavezzo, M. Pacenti, E. Casal Ide, A. Toniato, S. Toppo, G. Palu, and M. R. Pelizzo Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur. J. Endocrinol., July 1, 2008; 159(1): 77 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Babchia, A. Calipel, F. Mouriaux, A.-M. Faussat, and F. Mascarelli 17-AAG and 17-DMAG-Induced Inhibition of Cell Proliferation through B-Raf Downregulation in WTB-Raf-Expressing Uveal Melanoma Cell Lines Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2348 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Maat, E. Kilic, G. P. M. Luyten, A. de Klein, M. J. Jager, N. A. Gruis, and P. A. Van der Velden Pyrophosphorolysis Detects B-RAF Mutations in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 23 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Henriquez, C. Janssen, E. G. Kemp, and F. Roberts The T1799A BRAF Mutation Is Present in Iris Melanoma Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4897 - 4900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Calipel, F. Mouriaux, A.-L. Glotin, F. Malecaze, A.-M. Faussat, and F. Mascarelli Extracellular Signal-regulated Kinase-dependent Proliferation Is Mediated through the Protein Kinase A/B-Raf Pathway in Human Uveal Melanoma Cells J. Biol. Chem., April 7, 2006; 281(14): 9238 - 9250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Goemans, C. M. Zwaan, A. Harlow, A. H. Loonen, B. E. S. Gibson, K. Hahlen, D. Reinhardt, U. Creutzig, M. C. Heinrich, and G. J. L. Kaspers In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets Blood, November 15, 2005; 106(10): 3532 - 3537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C W Wong, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, the Cancer Genome Project, S T Yuen, and S Y Leung BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs J. Clin. Pathol., June 1, 2005; 58(6): 640 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Egan, J. A. Sosman, and W. J. Blot Sunlight and Reduced Risk of Cancer: Is The Real Story Vitamin D? J Natl Cancer Inst, February 2, 2005; 97(3): 161 - 163. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nambiar, A. Mirmohammadsadegh, R. Doroudi, A. Gustrau, A. Marini, G. Roeder, T. Ruzicka, and U. R. Hengge Signaling Networks in Cutaneous Melanoma Metastasis Identified by Complementary DNA Microarrays Arch Dermatol, February 1, 2005; 141(2): 165 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Griswold, L. J. Shen, P. La Rosee, S. Demehri, M. C. Heinrich, R. M. Braziel, L. McGreevey, A. D. Haley, N. Giese, B. J. Druker, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis Blood, November 1, 2004; 104(9): 2912 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gear, H. Williams, E. G. Kemp, and F. Roberts BRAF Mutations in Conjunctival Melanoma Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2484 - 2488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Goodall, S. Martinozzi, T. J. Dexter, D. Champeval, S. Carreira, L. Larue, and C. R. Goding Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by {beta}-Catenin Mol. Cell. Biol., April 1, 2004; 24(7): 2915 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Goodall, C. Wellbrock, T. J. Dexter, K. Roberts, R. Marais, and C. R. Goding The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation Mol. Cell. Biol., April 1, 2004; 24(7): 2923 - 2931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Edwards, M R Ward, H Wu, C A Medina, M S Brose, P Volpe, S Nussen-Lee, H M Haupt, A M Martin, M Herlyn, et al. Absence of BRAF mutations in UV-protected mucosal melanomas J. Med. Genet., April 1, 2004; 41(4): 270 - 272. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
